Ra-223 Dichloride in mCRPC: More Is Not Better

A multicenter, international phase II study found higher-dose and extended-dose therapy with Ra-223 did not improve survival or pain scores.

Source: CancerNetwork - June 20, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news